4 reports of this reaction
7.8% of all ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE reports
#1 most reported adverse reaction
FOETAL EXPOSURE DURING PREGNANCY is the #1 most commonly reported adverse reaction for ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE, manufactured by Kenvue Brands LLC. There are 4 FDA adverse event reports linking ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE to FOETAL EXPOSURE DURING PREGNANCY. This represents approximately 7.8% of all 51 adverse event reports for this drug.
Patients taking ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE who experience foetal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FOETAL EXPOSURE DURING PREGNANCY is moderately reported among ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to foetal exposure during pregnancy, the following adverse reactions have been reported for ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE:
The following drugs have also been linked to foetal exposure during pregnancy in FDA adverse event reports:
FOETAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 4 FDA reports for ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FOETAL EXPOSURE DURING PREGNANCY accounts for approximately 7.8% of all adverse event reports for ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience foetal exposure during pregnancy while taking ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.